Cargando…

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients

This study was designed to examine the relative safety and efficacy of sevelamer in the treatment of chronic kidney disease (CKD) patients in comparison to placebo, calcium carbonate (CC), or lanthanum carbonate (LC). The PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Qian, Zhong, Yuanlong, Yu, Xiqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243412/ https://www.ncbi.nlm.nih.gov/pubmed/37272189 http://dx.doi.org/10.1080/0886022X.2023.2210230

Ejemplares similares

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study
por: Chen, Wei, et al.
Publicado: (2022)

A Retrospective Single-Center Study of Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Children With Tumor Lysis Syndrome
por: Al Blewi, Sawsan M, et al.
Publicado: (2023)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
por: Nguyen, Hai V., et al.
Publicado: (2016)

Comparison of Sevelamer and Calcium Carbonate in Prevention of Hypomagnesemia in Hemodialysis Patients
por: Jandaghi, Elahe, et al.
Publicado: (2021)

Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011)

Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial
por: Takkavatakarn, Kullaya, et al.
Publicado: (2021)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
por: Nadin, Carole
Publicado: (2005)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial
por: Smith, Edward R., et al.
Publicado: (2020)

Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients
por: Ossareh, Shahrzad
Publicado: (2014)

A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis
por: Zhou, Tianbiao, et al.
Publicado: (2018)

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
por: GAO, ZHUO, et al.
Publicado: (2013)

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis
por: Chen, Lan, et al.
Publicado: (2018)

Hyperphosphatemia is not significantly associated with increased all-cause mortality in Korean hemodialysis patients
por: Wakasugi, Minako, et al.
Publicado: (2018)

Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients
por: Rosa-Diez, Guillermo, et al.
Publicado: (2016)

Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis—A Randomized Clinical Trial
por: Ketteler, Markus, et al.
Publicado: (2020)

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020)

Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
por: Koiwa, Fumihiko, et al.
Publicado: (2016)

Effects of Sevelamer Hydrochloride on Uremic Toxins Serum Indoxyl Sulfate and P-Cresyl Sulfate in Hemodialysis Patients
por: Lin, Cheng-Jui, et al.
Publicado: (2017)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis
por: Zhao, Lijuan, et al.
Publicado: (2021)

Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis
por: Hatakeyama, Shingo, et al.
Publicado: (2013)

Hyperphosphatemia Management in Patients with Chronic Kidney Disease
por: Shaman, Ahmed M., et al.
Publicado: (2016)

Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
por: Moon, Ju-Young, et al.
Publicado: (2015)

Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients
por: Jung, Jinwoo, et al.
Publicado: (2022)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence
por: Lloret, MªJesús, et al.
Publicado: (2013)

Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
por: Kubotera, Natsuki, et al.
Publicado: (2013)

Ischemic Colitis in Association with Sevelamer Crystals
por: Keri, K. C., et al.
Publicado: (2019)

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Sevelamer Carbonate Crystal-Induced Colitis
por: Lai, T., et al.
Publicado: (2020)

Update and critical appraisal of sevelamer in the management of chronic renal failure
por: Grinfeld, Jacob, et al.
Publicado: (2010)

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis
por: Fan, Stanley, et al.
Publicado: (2009)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Hyperphosphatemia and Outcomes in Critically Ill Patients: A Systematic Review and Meta-Analysis
por: Zheng, Wen-He, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ou50trinj40u9kv4lim77k6p6k